Skip to content

Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study

Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02654847
Enrollment
40
Registered
2016-01-13
Start date
2016-01-31
Completion date
2016-04-30
Last updated
2016-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension

Keywords

vasopressor, blood pressure, Cesarean section, spinal anesthesia

Brief summary

Spinal anesthesia is the most common anesthetic technique for elective Cesarean delivery (CD), but the most frequent unwanted side effect is hypotension, which can cause nausea and vomiting, as well as effects on the fetus. Prevention and treatment of maternal hypotension includes intravenous fluids and vasopressors. Phenylephrine is the most common vasopressor used for this purpose. However, it has been shown to reduce maternal heart rate and cardiac output, which may be a concern in an already compromised fetus. Norepinephrine is commonly used in high concentrations in intensive care and recent studies have suggested that in low concentrations it may be a better alternative to phenylephrine in elective CD, as it does not reduce the maternal heart rate or cardiac output. The optimum bolus dose of norepinephrine to prevent hypotension after spinal anesthesia in elective CD has not been elucidated. The investigators propose this study to determine the dose that would be effective in 90% of patients (ED90). A previous study by Ngan Kee et al, using continuous infusion of norepinephrine to prevent hypotension in elective CD, suggested a potency ratio for norepinephrine to phenylephrine of approximately 16:1. Hence, the investigators hypothesise that the ED90 will be approximately 6 µg, given that the current phenylephrine bolus dose at the investigators' institution is approximately 100 µg.

Detailed description

The use of norepinephrine to prevent and treat hypotension during cesarean delivery (CD) is new and data in the literature are scarce. A recent randomised controlled trial by Ngan Kee et al compared continuous infusions of norepinephrine and phenylephrine to prevent hypotension during CD. They showed that norepinephrine was effective at maintaining blood pressure, with a greater cardiac output and heart rate compared to phenylephrine. However, the effective bolus dose of norepinephrine needed to prevent maternal hypotension was not determined, and since this is a relatively new arena, no dose-response studies are available in the literature either. Therefore, it would be logical to establish the effective bolus dose of norepinephrine TO PREVENT HYPOTENSION during elective CD.

Interventions

DRUGNorepinephrine
DRUGNormal Saline

0.9% sodium chloride solution, used as a diluent.

Sponsors

Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Elective CD under spinal anesthesia * Normal singleton pregnancy beyond 36 weeks gestation * ASA physical status II/III * Weight 50-100 kg, height 150-180 cm * Age over 18 years * Informed consent

Exclusion criteria

* Patient refusal * Allergy or hypersensitivity to norepinephrine or sulfite * Preexisting or pregnancy-induced hypertension * Cardiovascular or cerebrovascular disease * Fetal abnormalities * History of diabetes, excluding gestational diabetes * Use of monoamine oxidase inhibitors, triptyline or imipramine antidepressants

Design outcomes

Primary

MeasureTime frameDescription
Systolic blood pressure30 minutesThe primary outcome of this study will be the success/response of the norepinephrine dose to maintain the systolic blood pressure at or above 80% of baseline, from induction of spinal anesthesia to delivery of the fetus.

Secondary

MeasureTime frameDescription
Presence of Vomiting30 minutesPresence of vomiting in patients from induction of spinal anesthesia to delivery of the fetus.
Hypertension: Systolic blood pressure at or above 120% of baseline30 minutesSystolic blood pressure at or above 120% of baseline, from induction of spinal anesthesia to delivery of the fetus.
Bradycardia: Heart rate less than 50 bpm30 minutesHeart rate less than 50 bpm, from induction of spinal anesthesia
Upper sensory level of anesthetic block, assessed by pinprick upon delivery30 minutesUpper sensory level of anesthesia, assessed by pinprick upon delivery
Umbilical artery pH24 hoursUmbilical artery pH
Umbilical artery partial pressure of carbon dioxide24 hoursUmbilical artery partial pressure of carbon dioxide
Umbilical artery partial pressure of oxygen24 hoursUmbilical artery partial pressure of oxygen
Presence of Nausea30 minutesPresence of nausea in patients from induction of spinal anesthesia to delivery of the fetus.
Umbilical artery base excess24 hoursUmbilical artery base excess
Umbilical vein pH24 hoursUmbilical vein pH
Umbilical vein partial pressure of carbon dioxide24 hoursUmbilical vein partial pressure of carbon dioxide
Umbilical vein partial pressure of oxygen24 hoursUmbilical vein partial pressure of oxygen
Umbilical vein bicarbonate24 hoursUmbilical vein bicarbonate
Umbilical vein base excess24 hoursUmbilical vein base excess
Umbilical artery bicarbonate24 hoursUmbilical artery bicarbonate

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026